New Guideline Recommends CYP2C19 Genotyping Before Clopidogrel Therapy
Lydia Kariuki, Managing Editor at American Pharmacogenomics Association, posted on LinkedIn:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Oct 6, 2026, 09:56Anitha Narayanamurthy: A Possible Missing Link in Unexplained Blood Test Abnormalities
-
Oct 6, 2026, 09:46Francois Roubille: Biomarkers and Long-Term Prognosis After Revascularised STEMI
-
Oct 6, 2026, 09:20EAS Rare Lipid Disorder Course – Advancing Lipid Disorder Education – European Atherosclerosis Society
-
Oct 6, 2026, 09:12Fionnuala Ní Áinle: Lisa Ryan’s First Thrombocalc VTE Research Report
-
Oct 6, 2026, 09:02David McIntosh: Preventable Maternal and Newborn Deaths – The Urgent Need for Action
-
Oct 6, 2026, 08:55Konstantin Yenkoyan: CAR-T, GLP-1 or Orexin – Who Will Take the 2026 Nobel?
-
Oct 6, 2026, 08:39Emily Bury: Putting Patients at the Centre of VTE Care
-
Oct 6, 2026, 07:44Carolina Moreira Ponce: Thrombosis Month – Why Prevention Starts With Risk Assessment
-
Oct 6, 2026, 07:03Laila Ahmed: Stroke Imaging – A Practical Radiology Approach